{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiciklkoqfza7xdr6yjzpisrnemopenpotohqlyipfi4vuipxofpby",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mnfcx66qzhe2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidpalnsxi5zwdmoq4awktp5uaone3rvvyf3brzsvjjgjr2fuvxw64"
    },
    "mimeType": "image/jpeg",
    "size": 12680
  },
  "path": "/2026/06/03/antengene-to-present-first-preclinical-data-on-atg-207-%ce%b1cd3-tgf-%ce%b2-bifunctional-fusion-protein-at-eular-2026/",
  "publishedAt": "2026-06-03T04:00:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will present the first preclinical data on ATG-207 (αCD3-TGF-β […]",
  "title": "Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026"
}